COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,032 Articles (22,627 medRxiv, 8,405 bioRxiv)

Most recent first Previous |  Page 1573: Articles 15721-15730  | Next

ReCOVer study: A Cross-sectional Observational Study to Identify the Rehabilitation Need in Post-discharge COVID-19 Survivors
Swarnakar, R., Yadav, S. L., V, S., Soni, K. D., Aggrawal, R., Trikha, A.
10.1101/2021.04.19.21255750 — Posted: 2021-04-22
B and T cell immune responses elicited by the BNT162b2 (Pfizer BioNTech) COVID-19 vaccine in nursing home residents
Torres, I., Albert, E., Gimenez, E., Alcaraz, M. J., Botija, P., Amat, P., Remigia, M. J., Beltran, M. J., Rodado, C., Huntley, D., Olea, B., Navarro, D.
10.1101/2021.04.19.21255723 — Posted: 2021-04-22
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2 specific CD8 T cell responses following COVID-19
Roukens, A. H. E., Konig, M., Dalebout, T., Tak, T., Azimi, S., Kruize, Y., Pothast, C. R., Hagedoorn, R. S., Arbous, S. M., Zhang, J. L. H., Verheij, M., Prins, C., Does, A. M., Hiemstra, P. S., Vries, J. J. C., Janse, J. J., Roestenberg, M., Myeni, S. K., Kikkert, M., Heemskerk, M. H. M., Yazdanbakhsh, M., Smits, H. H., Jochems, S. P., BEAT-COVID group, , COVID-19 LUMC group
10.1101/2021.04.19.21255727 — Posted: 2021-04-22
SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands
Petersen, M. S., Hansen, C. B., Kristiansen, M. F., Fjallsbak, J. P., Larsen, S., Hansen, J. L., Jarlhelt, I., Perez Alos, L., a Steig, B., Christiansen, D. H., Moller, L. F., Strom, M., Andorsdottir, G., Gaini, S., Weihe, P., Garred, P.
10.1101/2021.04.19.21255720 — Posted: 2021-04-22 Discussion: Onsite
No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
Shurrab, F. M., Humaira, F., Al-Absi, E. S., Al-Sadeq, D. W., Qotba, H., Yassine, H. M., Abu-Raddad, L. J., Nasrallah, G. K.
10.1101/2021.04.19.21255725 — Posted: 2021-04-22
Impact of social distancing measures on the daily number of new COVID-19 cases in Cote d'Ivoire: a retrospective cohort study
Porgo, T. V., Malloumb Boukar, K., Djallo, E., Quansah Amissah, R., Assy, C., Traore, A., Sorgho, G.
10.1101/2021.04.18.21255693 — Posted: 2021-04-22
Short time effect of Covid 19 pandemic on HbA1c and acute metabolic complications in children with type 1 diabetes
Arslanoglu, I., Akcali, F., Yavuzyilmaz, F., Sungur, M. A.
10.1101/2021.04.18.21255687 — Posted: 2021-04-22
A Caveat to Using Wearable Sensor Data for COVID-19 Detection: The Role of Behavioral Change after Receipt of Test Results
Cleary, J. L., Fang, Y., Sen, S., Wu, Z.
10.1101/2021.04.17.21255513 — Posted: 2021-04-22
Estimating SARS-CoV-2 reproduction number by infection location in Japan
Kurita, J., Hata, T., Sugawara, T., Ohkusa, Y., Hata, A.
10.1101/2021.04.13.21255296 — Posted: 2021-04-22
MARCH8 targets cytoplasmic lysine residues of various viral envelope glycoproteins
Zhang, Y., Ozono, S., Tada, T., Tobiume, M., Kameoka, M., Kishigami, S., Fujita, H., Tokunaga, K.
10.1101/2021.04.20.440588 — Posted: 2021-04-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).